诺华公司将以20亿美元的价格收购Excellergy, 以扩大免疫学产品线. Novartis to acquire Excellergy for up to $2B to expand immunology pipeline.

诺华公司同意以高达20亿美元的价格收购私营生物技术公司Excellergy, 以扩大其免疫学管道. Novartis agreed to acquire privately-held biotechnology company Excellergy for up to $2 billion to expand its immunology pipeline. 该交易主要集中在Excellergy的主要候选药物,即早期临床试验中的抗IgE抗体,旨在为食物过敏,疹和喘息提供改进的治疗方法. The deal focuses on Excellergy's lead drug candidate, an anti-IgE antibody in early clinical trials, aiming to offer improved treatments for food allergies, hives, and asthma. 公司在专利到期前进行了近期的采购,以加强产品线. This acquisition follows recent purchases to strengthen the company's product pipeline ahead of patent expirations.